Condition: Atrial Fibrillation (AF) · Stroke Prevention in Patients With Atrial Fibrillation · Left Atrial Appendage Closure · Sponsor: Boston Scientific Corporation
The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case. The study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.
This description comes directly from the study's public registry record.
Katherine A Beattie, Sr. Clinical Trial Manager, RN · +1 612 819 4540 · Katherine.beattie@bsci.com
Always discuss trial participation with your own doctor first.
| Klinicki bolnicki centar Zagreb | Zagreb, Croatia | Recruiting |
| Clinique Pasteur - Toulouse | Toulouse, France | Not Yet Recruiting |
| University Hospital of Salamanca | Salamanca, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07349121